Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147576 · ClinicalTrials.gov registry record · Phase 2
Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00147576 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 88 participants.
The verdict
NCT00147576, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866,087 in alcohol dependent subjects compared to placebo.
Interventions
- DRUG CP-866,087
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2003-12 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00147576
The ClinicalTrials.gov registry entry for NCT00147576 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-866,087 is the first listed.
NCT00147576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00147576 about?
NCT00147576 is a clinical study titled "Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.". Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866,087 in alcohol dependent subjects compared to placebo.
What is the current status of trial NCT00147576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2003-12. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00147576?
The interventions under investigation include: CP-866,087 (DRUG).
Who is sponsoring clinical trial NCT00147576?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.